The concerns I expressed re off site targeting would reasonably...

The concerns I expressed re off site targeting would reasonably be raised in any objective, science based discussion on the risk /reward of any therapeutic product, and I've been involved in many such project analyses in the past. I do consider the physiological consequences of those side effects resulting from secondary targeting of endocrine and neurocrine communication molecules to be somewhat different to surface antigen such as PSMA, so the analogy is not entirely accurate, but I do take your point, and it is probably the best available. I also agree that there appears to be no better therapeutic options at present (at least to my limited knowledge) and, like all leading edge therapeutic research, the trials have to be done, results analysed, refinements made, and further directions determined. Nevertheless, my concerns remain justified IMO.

As regards your later comments about the honesty of my sentiment, I guess we all have to read what is written, consider the veracity of comments made and decide whether they represent a genuine attempt to add to intelligent objective debate, or are subjectively motivated to derive superficial and trivial satisfaction. You decide.

I am a strong supporter of Clarity's various project developments and believe that all their diagnostic products and their PSMA therapies are world class. I expect and hope that in time they will become the SOC therapies and best in class diagnostics. The Sabre trial results were brilliant by any standard, and, as a result, I added another 5,500 shares to my portfolio on Friday.

Let me also congratulate you on the consistent quality of your frequent postings on Clarity's threads. They are always thoughtful, educational, and a pleasure to read. Indeed there are so few comparable posters on any of the HotCopper threads I visit these days. One of the reasons I am very selective with the contributions I choose to make
Cheers